154 related articles for article (PubMed ID: 2965136)
1. Teicoplanin in infections caused by methicillin-resistant staphylococci.
Drabu YJ; Walsh B; Blakemore PH; Mehtar S
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():89-92. PubMed ID: 2965136
[TBL] [Abstract][Full Text] [Related]
2. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results.
Van Laethem Y; Hermans P; De Wit S; Goosens H; Clumeck N
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():81-7. PubMed ID: 2965135
[TBL] [Abstract][Full Text] [Related]
3. Teicoplanin in the treatment of infections caused by coagulase-negative staphylococci.
Harding I; Garaud JJ
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():93-103. PubMed ID: 2965137
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics of Methicillin-resistant Coagulase-negative Staphylococcal Bacteremia in a Tertiary Hospital.
Yamada K; Namikawa H; Fujimoto H; Nakaie K; Takizawa E; Okada Y; Fujita A; Kawaguchi H; Nakamura Y; Abe J; Kaneko Y; Kakeya H
Intern Med; 2017; 56(7):781-785. PubMed ID: 28381743
[TBL] [Abstract][Full Text] [Related]
5. Activity of teicoplanin in localized experimental infections in rats.
Arioli V; Berti M; Candiani G
J Hosp Infect; 1986 Mar; 7 Suppl A():91-9. PubMed ID: 2871103
[TBL] [Abstract][Full Text] [Related]
6. Treatment of infections by staphylococci and other gram-positive bacteria with teicoplanin: an open study.
Pauluzzi S; Del Favero A; Menichetti F; Baratta E; Moretti VM; Di Filippo P; Pasticci MB; Guerciolini R; Patoia L; Frongillo RF
J Antimicrob Chemother; 1987 Sep; 20(3):431-8. PubMed ID: 2960643
[TBL] [Abstract][Full Text] [Related]
7. Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group, USA.
LeFrock JL; Ristuccia AM; Ristuccia PA; Quenzer RW; Haggerty PG; Allen JE; Lettau LA; Schwartz R; Appleby D
Eur J Surg Suppl; 1992; (567):9-13. PubMed ID: 1381644
[TBL] [Abstract][Full Text] [Related]
8. Teicoplanin in the treatment of infections by staphylococci, Clostridium difficile and other gram-positive bacteria.
de Lalla F; Santoro D; Rinaldi E; Suter F; Cruciani M; Guaglianone MH; Rizzardini G; Pellegata G
J Antimicrob Chemother; 1989 Jan; 23(1):131-42. PubMed ID: 2526109
[TBL] [Abstract][Full Text] [Related]
9. Cephalosporins, vancomycin, aminoglycosides and other drugs, especially in combination, for the treatment of methicillin-resistant staphylococcal infections.
Klastersky J; Van der Auwera P
J Antimicrob Chemother; 1986 Mar; 17 Suppl A():19-24. PubMed ID: 2940212
[TBL] [Abstract][Full Text] [Related]
10. Glycopeptides in the treatment of staphylococcal infections.
Daschner FD; Kropec A
Eur J Clin Microbiol Infect Dis; 1995; 14 Suppl 1():S12-7. PubMed ID: 7729466
[TBL] [Abstract][Full Text] [Related]
11. Long-term intramuscular teicoplanin treatment of chronic osteomyelitis due to oxacillin-resistant Staphylococcus aureus in outpatients.
Testore GP; Uccella I; Sarrecchia C; Mattei A; Impagliazzo A; Sordillo P; Andreoni M
J Chemother; 2000 Oct; 12(5):412-5. PubMed ID: 11128561
[TBL] [Abstract][Full Text] [Related]
12. [Methicillin resistant staphylococci].
Afanas'eva TI
Antibiot Khimioter; 1998; 43(6):29-31. PubMed ID: 9644532
[No Abstract] [Full Text] [Related]
13. Methicillin-resistant staphylococci in clean surgery. Is there a role for prophylaxis?
Mini E; Nobili S; Periti P
Drugs; 1997; 54 Suppl 6():39-52. PubMed ID: 9474480
[TBL] [Abstract][Full Text] [Related]
14. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Gaona Álvarez C; Sánchez Silos RM; Hernández Rastrollo R; Martínez Tallo E; Cordero Carrasco JL
Rev Esp Quimioter; 2012 Mar; 25(1):25-30. PubMed ID: 22488538
[TBL] [Abstract][Full Text] [Related]
15. Current problems of chemotherapy of infections with coagulase-negative staphylococci.
Davies AJ; Stone JW
Eur J Clin Microbiol; 1986 Jun; 5(3):277-81. PubMed ID: 3527698
[TBL] [Abstract][Full Text] [Related]
16. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy.
Falcone M; Russo A; Pompeo ME; Vena A; Marruncheddu L; Ciccaglioni A; Grossi P; Mancini C; Novelli A; Stefani S; Venditti M
Int J Antimicrob Agents; 2012 Jan; 39(1):64-8. PubMed ID: 22047703
[TBL] [Abstract][Full Text] [Related]
17. Clinical comparative study on the activity of cefamandole in the treatment of serious staphylococcal infections caused by methicillin-susceptible and methicillin-resistant strains.
Frongillo RF; Donati L; Federico G; Martino P; Moroni M; Ortona L; Palumbo M; Pasticci BM; Pizzigallo E; Privitera G
Antimicrob Agents Chemother; 1986 May; 29(5):789-96. PubMed ID: 3637066
[TBL] [Abstract][Full Text] [Related]
18. Coagulase-negative staphylococci emerging during teicoplanin therapy and the determination of their sensitivity.
Jones RN
J Antimicrob Chemother; 1992 Jun; 29(6):725-7. PubMed ID: 1387134
[No Abstract] [Full Text] [Related]
19. New antimicrobial agents for methicillin-resistant Staphylococcus aureus.
Kollef MH
Crit Care Resusc; 2009 Dec; 11(4):282-6. PubMed ID: 20001879
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic-associated diarrhoea and methicillin-resistant Staphylococcus aureus.
McDonald M; Ward P; Harvey K
Med J Aust; 1982 May; 1(11):462-4. PubMed ID: 7048039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
